<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H25B1A1780A254DD294233D3BE491E899" key="H" public-private="public">
	<metadata>
<dublinCore>
<dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">113 HR 5854 IH: To allow the importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document.</dc:title>
<dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">U.S. House of Representatives</dc:publisher>
<dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2014-12-11</dc:date>
<dc:format xmlns:dc="http://purl.org/dc/elements/1.1/">text/xml</dc:format>
<dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">EN</dc:language>
<dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>2d Session</session>
		<legis-num>H. R. 5854</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20141211">December 11, 2014</action-date>
			<action-desc>
        <sponsor name-id="G000556">Mr. Grayson</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title display="yes">To allow the importation, distribution, and sale of investigational drugs and devices intended for 
use by terminally ill patients who execute an informed consent document.</official-title>
	</form>
	<legis-body id="HD030454E17364C6AB2BF4C0D4308DB56" style="OLC">
		<section id="H08FD6F0EA8794569AADC3AD790FC68B5" section-type="section-one">
      <enum>1.</enum>
      <header>Drugs and devices for use by terminally ill patients</header>
			<text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act">Federal Food, Drug, and Cosmetic Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:561">section 561</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/360bbb">21 U.S.C.
			 360bbb</cato:entity-ref>)</cato:entity> the following:</text>
      <quoted-block display-inline="no-display-inline" id="idDE95FE7CFBEF4C7EB0C1902A91775AB3" style="OLC">
        <section id="id6A9FE5F1D87B412D806E869A3F12444D">
          <enum>561A.</enum>
          <header>Drugs and devices for use by terminally ill patients</header>
          <subsection id="id9A6F0553FC2B479A925EBE69B750BFB8">
            <enum>(a)</enum>
            <header>In general</header>
            <text>Nothing in this Act or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> prevents or restricts, and the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-id="7524" entity-type="federal-body">Food and Drug Administration</cato:entity-ref> shall not implement or enforce any provision
			 of law preventing or restricting, the importation, distribution, or sale
			 of an investigational drug or device intended for use by a terminally ill
			 patient in accordance with subsection (b).</text>
          </subsection>
          <subsection id="id979744153EF946C1BBE227938E60F83F">
            <enum>(b)</enum>
            <header>Patient requirements</header>
            <text>In order for an investigational drug or device to be intended for use in accordance with this
			 subsection, such drug or device must be intended for use by a patient who
			 has—</text>
            <paragraph id="idF3CF6FAC3B9E455B96A21E61BF19A1CC">
              <enum>(1)</enum>
              <text>been diagnosed with a terminal illness by a licensed physician;</text>
            </paragraph>
            <paragraph id="id2277C9C60E7249798EA52E17526FB330">
              <enum>(2)</enum>
              <text>been informed by a licensed physician that no drug or device that is lawfully marketed in the
			 United States is likely to cure the illness; and</text>
            </paragraph>
            <paragraph id="id6A5FA53586F5434FAE2C626D0AE026C0">
              <enum>(3)</enum>
              <text>executed a written informed consent document that states—</text>
              <subparagraph id="id6C789B2C5BC34CAFA416DE770B9A8CFA">
                <enum>(A)</enum>
                <text>the known and potential risks and benefits of such drug or device; and</text>
              </subparagraph>
              <subparagraph id="idB9510150094B430BB3FDF10C27FB8807">
                <enum>(B)</enum>
                <text>any indications of the illness for which a drug or device is lawfully marketed, or for which
			 treatment is otherwise available, in the United States.</text>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="id5080A28F3BA24A6C8D5630A490A221E4">
            <enum>(c)</enum>
            <header>Definition of investigational drug or device</header>
            <text>In this section, the term <term>investigational drug or device</term> means a drug or device that—</text>
            <paragraph id="idBC811F15C3FF4AE893D1966DCF6BA9B1">
              <enum>(1)</enum>
              <text>has not yet been approved, licensed, or cleared for commercial distribution under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505</cato:entity-ref>,
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:k">510(k)</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:515">515 of this Act</cato:entity-ref> or <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                  <cato:entity-ref entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref>
			 (<external-xref legal-doc="usc" parsable-cite="usc/42/262">
                  <cato:entity-ref entity-type="uscode" value="usc/42/262">42 U.S.C. 262</cato:entity-ref>
                </external-xref>)</cato:entity>, and cannot otherwise be lawfully marketed in the United
			 States; and</text>
            </paragraph>
            <paragraph id="id7E29FDAC133C4DE795C20398E2D67EB1">
              <enum>(2)</enum>
              <text>is or has been the subject of one or more clinical trials.</text>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
    </section>
  </legis-body>
</bill>